Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down prior to trading on Friday . The stock had previously closed at $10.27, but opened at $9.66. Telix Pharmaceuticals shares last traded at $9.4810, with a volume of 60,777 shares.

Analyst Ratings Changes

A number of equities analysts have commented on TLX shares. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Citigroup boosted their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Stock Down 7.3%

The business’s 50 day moving average price is $9.83 and its two-hundred day moving average price is $8.74. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. Equities analysts forecast that Telix Pharmaceuticals Limited will post 0.09 earnings per share for the current year.

Insider Buying and Selling at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch purchased 33,435 shares of Telix Pharmaceuticals stock in a transaction dated Wednesday, April 29th. The stock was bought at an average cost of $14.87 per share, with a total value of $497,178.45. Following the purchase, the chief executive officer owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLX. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $975,000. Jane Street Group LLC acquired a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $564,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $213,000. Rhumbline Advisers lifted its stake in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Telix Pharmaceuticals during the third quarter valued at approximately $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.